Skip to main content
. 2023 Dec 21;16(1):48. doi: 10.3390/cancers16010048

Figure 1.

Figure 1

Analyses of miR-410 expression in PCa clinical samples and cell lines. (A) miR-410 expression analyses in matched tumor/normal PCa tissues (n = 9) as assessed by real-time PCR. RNU48 was used as an endogenous control. Error bars represent SEM. (B) miR-410 expression in TCGA dataset of prostate adenocarcinomas. Expression in normal tissues (n = 51) and primary prostate adenocarcinomas (n = 490) are represented. (C) miR-410 expression analyses in primary PCa stratified by Gleason score. (D) miR-410 expression in normal tissues vs. prostate adenocarcinomas with N0 or N1 tumor nodal status. (E) miR-410 expression in normal prostate tissues and various subtypes of prostate adenocarcinomas. (F) miR-410 expression analyses in normal immortalized prostate epithelial cell line RWPE-1 and indicated PCa cell lines. RNU48 was used as an endogenous control. (G) miR-410 expression in microdissected CRPC-Adenocarcinomas and CRPPC-NE clinical samples as assessed by real-time PCR analyses. RNU48 was used as an endogenous control. * denotes p < 0.05.